A trio of stocks made an impressive leap in their Benzinga Edge value scores this week, with one standout making a 138% jump.

DexCom (DXCM) is under the spotlight after several class action lawsuits were filed claiming the company made unauthorized changes to its G6 and G7 glucose monitoring devices. These changes could ...

Dexcom has issued a Class I recall for its G6 Android app due to crashes that could cause users to miss critical glucose ...

A software defect could cause the app to terminate, resulting in missed alerts or alarms. Dexcom required users to download ...

Medical device company DexCom (NASDAQ:DXCM) announced better-than-expected revenue in Q3 CY2025, with sales up 21.6% year on ...

DexCom's third quarter was met with a negative market reaction despite outpacing Wall Street’s revenue and adjusted EPS ...

Shares of DexCom Inc. slipped 5.21% to $55.00 Friday, on what proved to be an all-around favorable trading session for the ...

Dexcom is facing scrutiny and class-action lawsuits over alleged safety and accuracy issues with its G7 monitor.

DexCom, Inc. DXCM reported third-quarter 2025 adjusted earnings per share (EPS) of 61 cents, which beat the Zacks Consensus ...

Medical device company DexCom (NASDAQ:DXCM) will be reporting results this Thursday after market close. Here’s what you need ...

Q3 2025 Earnings Call Transcript October 30, 2025 DexCom, Inc. beats earnings expectations. Reported EPS is $0.61, ...

Thank you, operator, and welcome to DexCom's Third Quarter 2025 Earnings Call. Our agenda begins with Jake Leach, DexCom's President and Interim CEO, who will summarize our recent highlights and ...